NEW PHARMACOLOGICAL AND PHYSIOLOGICAL-ASPECTS OF GROWTH HORMONE(II) -THERAPEUTIC APPLICATIONS IN ADULTS

Normal human ageing is associated with changes in body composition whi ch include a decrease in muscle mass and strength, bone mass loss and increase in adipose mass. A physiological decrease in growth hormone ( GH) and IGF-I secretion accompanies these changes. Many of the physiol ogical changes that accompany normal human ageing are very similar to those found in GH deficient patients. Nevertheless, responsiveness to exogenous administered GH persists with advancing age. GH administrati on to elderly individuals has produced an decrease in fat mass and an increase in lean body mass, being this finding consistent with the hyp othesis that GH deficiency could be a contributing cause to senescent changes in some elderly individuals. GH treatment has also been used w ith encouraging results in adult subjects with isolated or combined GH deficiency. On the other hand, several clinical studies have recently shown the efficienty of GH treatment on diverse pathological processe s such as severe catabolic states (surgery, sepsis, trauma, buns), ost eoporosis, diabetic ulcers and obesity. The most frequent side effects are sodium and water retention, impairment in glucose tolerance and c arpal tunnel syndrome, although in general the treatment has been well tolerated. The clear definition of the therapeutical aplications of G H in the adult warrants further clinical investigation.